These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

576 related articles for article (PubMed ID: 34607067)

  • 1. Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: A systematic review and meta-analysis.
    Fatima K; Moeed A; Waqar E; Atif AR; Kamran A; Rizvi H; Suri NF; Haider H; Shuja SH; Khalid M; Minhas AMK
    Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101816. PubMed ID: 34607067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Eslami L; Merat S; Malekzadeh R; Nasseri-Moghaddam S; Aramin H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008623. PubMed ID: 24374462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statin liver safety in non-alcoholic fatty liver disease: A systematic review and metanalysis.
    Pastori D; Pani A; Di Rocco A; Menichelli D; Gazzaniga G; Farcomeni A; D'Erasmo L; Angelico F; Del Ben M; Baratta F
    Br J Clin Pharmacol; 2022 Feb; 88(2):441-451. PubMed ID: 34133035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of metformin administration on liver enzymes and body composition in non-diabetic patients with non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis: An up-to date systematic review and meta-analysis of randomized controlled trials.
    Jalali M; Rahimlou M; Mahmoodi M; Moosavian SP; Symonds ME; Jalali R; Zare M; Imanieh MH; Stasi C
    Pharmacol Res; 2020 Sep; 159():104799. PubMed ID: 32278041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of sodium-glucose cotransporter-2 inhibitors and thiazolidinediones for management of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Hameed I; Hayat J; Marsia S; Samad SA; Khan R; Siddiqui OM; Khan MO; Malik S; Fatima K; Fudim M; Krasuski RA
    Clin Res Hepatol Gastroenterol; 2023 May; 47(5):102111. PubMed ID: 36931466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statins' efficacy in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Boutari C; Pappas PD; Anastasilakis D; Mantzoros CS
    Clin Nutr; 2022 Oct; 41(10):2195-2206. PubMed ID: 36081293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Dong Y; Lv Q; Li S; Wu Y; Li L; Li J; Zhang F; Sun X; Tong N
    Clin Res Hepatol Gastroenterol; 2017 Jun; 41(3):284-295. PubMed ID: 28065744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Mediterranean diet on liver enzymes: a systematic review and meta-analysis of randomised controlled trials.
    Sangouni AA; Hassani Zadeh S; Mozaffari-Khosravi H; Hosseinzadeh M
    Br J Nutr; 2022 Oct; 128(7):1231-1239. PubMed ID: 34165054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alanine Aminotransferase and Gamma-Glutamyl Transpeptidase Predict Histologic Improvement in Pediatric Nonalcoholic Steatohepatitis.
    Newton KP; Lavine JE; Wilson L; Behling C; Vos MB; Molleston JP; Rosenthal P; Miloh T; Fishbein MH; Jain AK; Murray KF; Schwimmer JB;
    Hepatology; 2021 Mar; 73(3):937-951. PubMed ID: 32416645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Zafar Y; Rashid AM; Siddiqi AK; Ellahi A; Ahmed A; Hussain HU; Ahmed F; Menezes RG; Siddiqi TJ; Maniya MT
    Clin Res Hepatol Gastroenterol; 2022; 46(7):101970. PubMed ID: 35659603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of dapagliflozin in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Sun L; Deng C; Gu Y; He Y; Yang L; Shi J
    Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101876. PubMed ID: 35321843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
    Zhu Y; Xu J; Zhang D; Mu X; Shi Y; Chen S; Wu Z; Li S
    Front Endocrinol (Lausanne); 2021; 12():769069. PubMed ID: 34956080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of melatonin supplementation on liver indices in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized clinical trials.
    Mansoori A; Salimi Z; Hosseini SA; Hormoznejad R; Jafarirad S; Bahrami M; Asadi M
    Complement Ther Med; 2020 Aug; 52():102398. PubMed ID: 32951697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statins for the Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis.
    Dai W; Xu B; Li P; Weng J
    Am J Ther; 2023 Jan-Feb 01; 30(1):e17-e25. PubMed ID: 36608070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Different Exercise Methods on Non-Alcoholic Fatty Liver Disease: A Meta-Analysis and Meta-Regression.
    Xiong Y; Peng Q; Cao C; Xu Z; Zhang B
    Int J Environ Res Public Health; 2021 Mar; 18(6):. PubMed ID: 33801028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GLP-1 Receptor Agonist Effects on Lipid and Liver Profiles in Patients with Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis.
    Rezaei S; Tabrizi R; Nowrouzi-Sohrabi P; Jalali M; Atkin SL; Al-Rasadi K; Jamialahmadi T; Sahebkar A
    Can J Gastroenterol Hepatol; 2021; 2021():8936865. PubMed ID: 34805029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials.
    He XX; Wu XL; Chen RP; Chen C; Liu XG; Wu BJ; Huang ZM
    PLoS One; 2016; 11(10):e0162368. PubMed ID: 27711128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does aerobic exercise reduce NASH and liver fibrosis in patients with non-alcoholic fatty liver disease? A systematic literature review and meta-analysis.
    Houttu V; Bouts J; Vali Y; Daams J; Grefhorst A; Nieuwdorp M; Holleboom AG
    Front Endocrinol (Lausanne); 2022; 13():1032164. PubMed ID: 36407307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin E supplementation in the treatment on nonalcoholic fatty liver disease (NAFLD): Evidence from an umbrella review of meta-analysis on randomized controlled trials.
    Wang MY; Prabahar K; Găman MA; Zhang JL
    J Dig Dis; 2023; 24(6-7):380-389. PubMed ID: 37503812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.